SG Americas Securities LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 91.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,654 shares of the company’s stock after acquiring an additional 7,941 shares during the quarter. SG Americas Securities LLC’s holdings in Mirum Pharmaceuticals were worth $431,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. grew its position in shares of Mirum Pharmaceuticals by 25.3% in the 3rd quarter. BlackRock Inc. now owns 1,749,349 shares of the company’s stock worth $36,754,000 after buying an additional 353,337 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Mirum Pharmaceuticals by 26.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,244,925 shares of the company’s stock worth $26,155,000 after buying an additional 261,950 shares during the last quarter. Tang Capital Management LLC grew its position in shares of Mirum Pharmaceuticals by 148.9% in the 4th quarter. Tang Capital Management LLC now owns 1,120,000 shares of the company’s stock worth $21,840,000 after buying an additional 670,000 shares during the last quarter. State Street Corp grew its position in shares of Mirum Pharmaceuticals by 258.5% in the 3rd quarter. State Street Corp now owns 988,962 shares of the company’s stock worth $20,778,000 after buying an additional 713,095 shares during the last quarter. Finally, Polar Capital Holdings Plc bought a new stake in shares of Mirum Pharmaceuticals in the 1st quarter worth approximately $21,441,000.
Insider Buying and Selling at Mirum Pharmaceuticals
In other news, CEO Christopher Peetz sold 5,498 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $25.65, for a total value of $141,023.70. Following the completion of the transaction, the chief executive officer now owns 115,334 shares in the company, valued at $2,958,317.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Michael G. Grey sold 14,216 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $32.00, for a total value of $454,912.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Peetz sold 5,498 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $25.65, for a total value of $141,023.70. Following the completion of the sale, the chief executive officer now directly owns 115,334 shares of the company’s stock, valued at approximately $2,958,317.10. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 162,678 shares of company stock worth $4,323,280 and sold 26,517 shares worth $772,439. 24.06% of the stock is owned by company insiders.
Mirum Pharmaceuticals Trading Up 2.5 %
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.11). The company had revenue of $37.50 million for the quarter, compared to analysts’ expectations of $30.00 million. Mirum Pharmaceuticals had a negative net margin of 152.27% and a negative return on equity of 103.59%. Research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.41 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have recently weighed in on MIRM. Raymond James lifted their price objective on Mirum Pharmaceuticals from $79.00 to $84.00 and gave the stock a “strong-buy” rating in a research report on Monday, August 21st. JMP Securities started coverage on Mirum Pharmaceuticals in a research report on Wednesday, September 20th. They set an “outperform” rating and a $70.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, September 13th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $53.33.
View Our Latest Stock Analysis on MIRM
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
See Also
- Five stocks we like better than Mirum Pharmaceuticals
- How to Start Investing in Real Estate
- Nursing Home REITs: The Surprise Heroes of High Yield Investing
- Are Penny Stocks a Good Fit for Your Portfolio?
- Energy Stocks Shine as High Oil Prices Boost Dividend Yields
- What is the Hang Seng index?
- Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
